Appointments Jobs About Search Education & Research Clinical Trials Health Information Medical Services

Publications - Thomas M . Pisansky, M.D.

Back to Research Profile

  1. Halyard MY, Pisansky TM, Dueck AC, Suman VJ, Pierce LJ, Solin LJ, Marks LB, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil S, Perez EA. Reply to N. Magne et al. J Clin Oncol 2009 Nov 02. [Epub ahead of print]
    View PubMed
  2. Peterson JL, Buskirk SJ, Heckman MG, Crook JE, Ko SJ, Wehle MJ, Igel TC, Prussak KA, Pisansky TM. Late toxicity after postprostatectomy salvage radiation therapy. Radiother Oncol 2009 Nov; 93(2):203-6. Epub 2009 Sep 18.
    View PubMed
  3. Lawton CAF, Michalski J, El-Naqa I, Kuban D, Lee WR, Rosenthal SA, Zietman A, Sandler H, Shipley W, Ritter M, Valicenti R, Catton C, Roach M, Pisansky TM, Seider M. Variation in the definition of clinical target volumes for pelvic nodal conformal radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2009 Jun 1; 74(2):377-82.
    View PubMed
  4. Halyard MY, Pisansky TM, Dueck AC, Suman V, Pierce L, Solin L, Marks L, Davidson N, Martino S, Kaufman P, Kutteh L, Dakhil SR, Perez EA. Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. J Clin Oncol 2009 Jun 1; 27(16):2638-44. Epub 2009 Apr 06.
    View PubMed
  5. Parker AS, Heckman MG, Wu KJ, Crook JE, Hilton TW, Pisansky TM, Bernard JR, Schild SE, Khor LY, Hammond EH, Pollack A, Buskirk SJ. Evaluation of Ki-67 Staining Levels as an Independent Biomarker of Biochemical Recurrence After Salvage Radiation Therapy for Prostate Cancer. Int J Radiat Oncol Biol Phys 2009 May 21. [Epub ahead of print]
    View PubMed
  6. Pisansky TM, Gold DG, Furutani KM, Macdonald OK, McLaren RH, Mynderse LA, Wilson TM, Hebl JR, Choo R. High-dose-rate brachytherapy in the curative treatment of patients with localized prostate cancer. Mayo Clin Proc 2008 Dec; 83(12):1364-72.
    View PubMed
  7. Feng M, Hanlon AL, Pisansky TM, Kuban D, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Pollack A, Kestin LL, Valicenti RK, DeWeese TL, Sandler HM. Predictive factors for late genitourinary and gastrointestinal toxicity in patients with prostate cancer treated with adjuvant or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2007 Aug 1; 68(5):1417-23. Epub 2007 Apr 06.
    View PubMed
  8. Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, Anscher MS, Michalski JM, Sandler HM, Lin DW, Forman JD, Zelefsky MJ, Kestin LL, Roehrborn CG, Catton CN, DeWeese TL, Liauw SL, Valicenti RK, Kuban DA, Pollack A. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007 May 20; 25(15):2035-41.
    View PubMed
  9. Zelefsky MJ, Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Pisansky TM, Elshaikh M, Horwitz EM. Multi-institutional analysis of long-term outcome for stages T1-T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007 Feb 1; 67(2):327-33.
  10. Lawton CA, DeSilvio M, Lee WR, Gomella L, Grignon D, Gillin M, Morton G, Pisansky T, Sandler H. Results of a phase II trial of transrectal ultrasound-guided permanent radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (Radiation Therapy Oncology Group 98-05). Int J Radiat Oncol Biol Phys 2007 Jan 1; 67(1):39-47.
    View PubMed
  11. Ray ME, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Zelefsky MJ, Zietman AL, Kuban DA. Nadir prostate-specific antigen within 12 months after radiotherapy predicts biochemical and distant failure. Urology 2006 Dec; 68(6):1257-62. Epub 2006 Dec 04.
    View PubMed
  12. Pisansky TM. External-beam radiotherapy for localized prostate cancer. N Engl J Med 2006 Oct 12; 355(15):1583-91.
    View PubMed
  13. Horwitz EM, Levy LB, Thames HD, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. Biochemical and clinical significance of the posttreatment prostate-specific antigen bounce for prostate cancer patients treated with external beam radiation therapy alone: a multiinstitutional pooled analysis. Cancer 2006 Oct 1; 107(7):1496-502.
    View PubMed
  14. Choo R, Kawakami J, Siemens R, Davis BJ, Brundage M, Pisansky TM. Two different perspectives in the management of pT3 and/or margin-positive prostate cancer after radical prostatectomy. BJU Int 2006 Oct; 98(4):773-6.
    View PubMed
  15. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, Collie AC, Ferrigni RG, Myers RP, Prussak KA, Heckman MG, Crook JE, Parkert AS, Igel TC. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: Evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006 Sep; 176(3):985-90.
    View PubMed
  16. Buskirk SJ, Pisansky TM, Schild SE, Macdonald OK, Wehle MJ, Kozelsky TF, Collie AC, Ferrigni RG, Myers RP, Prussak KA, Heckman MG, Crook JE, Parker AS, Igel TC. Salvage radiotherapy for isolated prostate specific antigen increase after radical prostatectomy: evaluation of prognostic factors and creation of a prognostic scoring system. J Urol 2006 Sep; 176(3):985-90.
    View PubMed
  17. Kuban DA, Levy LB, Potters L, Beyer DC, Blasko JC, Moran BJ, Ciezki JP, Zietman AL, Zelefsky MJ, Pisansky TM, Elshaikh M, Horwitz EM. Comparison of biochemical failure definitions for permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2006 Aug 1; 65(5):1487-93. Epub 2006 Jun 05.
    View PubMed
  18. Thames HD, Kuban DA, DeSilvio ML, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Increasing external beam dose for T1-T2 prostate cancer: effect on risk groups. Int J Radiat Oncol Biol Phys 2006 Jul 15; 65(4):975-81. Epub 2006 Jun 05.
    View PubMed
  19. Ingle JN, Suman VJ, Mailliard JA, Kugler JW, Krook JE, Michalak JC, Pisansky TM, Wold LE, Donohue JH, Goetz MP, Perez EA. Randomized trial of tamoxifen alone or combined with fluoxymesterone as adjuvant therapy in postmenopausal women with resected estrogen receptor positive breast cancer. North Central Cancer Treatment Group Trial 89-30-52. Breast Cancer Res Treat 2006 Jul; 98(2):217-22. Epub 2006 Mar 15.
    View PubMed
  20. Ray ME, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Shipley WU, Zelefsky MJ, Zietman AL, Kuban DA. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis. Int J Radiat Oncol Biol Phys 2006 Mar 15; 64(4):1140-50. Epub 2005 Sep 29.
    View PubMed
  21. Gillin MT, Dunning BF, Lawton CA, Foley WD, Byhardt RW, Morton G, Baikadi M, Pisansky TT, Michalski JM, Ibbott G, Lopez F. Quality assurance methods for the first Radiation Therapy Oncology Group permanent prostate implant protocol. Brachytherapy 2006; 5(3):152-6.
    View PubMed
  22. Schallenkamp JM, Herman MG, Kruse JJ, Pisansky TM. Prostate position relative to pelvic bony anatomy based on intraprostatic gold markers and electronic portal imaging. International Journal of Radiation Oncology, Biology, Physics 2005 Nov 1; 63(3):800-11.
  23. Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2005 Nov 1; 63(3):795-9.
  24. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE, Davidson NE, Tan-Chiu E, Martino S, Paik S, Kaufman PA, Swain SM, Pisansky TM, Fehrenbacher L, Kutteh LA, Vogel VG, Visscher DW, Yothers G, Jenkins RB, Brown AM, Dakhil SR, Mamounas EP, Lingle WL, Klein P Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. New Engl J Med 2005 Oct 20; 353(16):1673-84.
    View PubMed
  25. Feigenberg SJ, Lee WR, Desilvio ML, Winter K, Pisansky TM, Bruner DW, Lawton C, Morton G, Baikadi M, Sandler H. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05. Int J Radiat Oncol Biol Phys 2005 Jul 15; 62(4):956-64.
    View PubMed
  26. Pisansky TM. External beam radiotherapy as curative treatment of prostate cancer. Mayo Clin Proc 2005 Jul; 80(7):883-98.
    View PubMed
  27. Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL. Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: A multi-institutional pooled analysis. J Urol 2005 Mar; 173(3):797-802.
    View PubMed
  28. Kupelian P, Kuban D, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: The combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys 2005 Feb 1; 61(2):415-9.
    View PubMed
  29. Kuban D, Thames H, Levy L, Horwitz E, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Failure definition-dependent differences in outcome following radiation for localized prostate cancer: Can one size fit all? Int J Radiat Oncol Biol Phys 2005 Feb 1; 61(2):409-14.
    View PubMed
  30. Wittmer MH, Pisansky TM, Kruse JJ, Herman MG. Patient-specific daily pretreatment setup protocol using electronic portal imaging for radiation therapy. Journal of Applied Clinical Medical Physics 2005; 6(4):1-13.
    View PubMed
  31. Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Herman MG, King BF, Geyer SM. Prostate volume measurement by transrectal ultrasound and computed tomography before and after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004 Nov 1; 60(3):767-76.
    View PubMed
  32. Solhjem MC, Davis BJ, Pisansky TM, Wilson TM, Mynderse LA, Hillman DW, Herman MG, King BF. Prostate volume before and after permanent prostate brachytherapy in patients receiving neoadjuvant androgen suppression. Cancer J 2004 Nov-Dec; 10(6):343-8.
    View PubMed
  33. Eshleman JS, Davis BJ, Pisansky TM, Wilson TM, Haddock MG, King BF, Darby CH, Lajoie WN, Oberg AL. Radioactive seed migration to the chest after transperineal interstitial prostate brachytherapy: Extraprostatic seed placement correlates with migration. Int J Radiat Oncol Biol Phys 2004 Jun 1; 59(2):419-25.
    View PubMed
  34. Davis BJ, Brinkmann DH, Kruse JJ, Herman MG, LaJoie WN, Schwartz DJ, Pisansky TM, Kline RW. Selective identification of different brachytherapy sources, ferromagnetic seeds, and fiducials in the prostate using an automated seed sorting algorithm. Brachytherapy 2004; 3(2):106-12.
    View PubMed
  35. Pisansky TM. Use of neoadjuvant and adjuvant therapy to prevent or delay recurrence of prostate cancer in patients undergoing radiation treatment for prostate cancer. Urology 2003 Dec 29; 62(6B Suppl S):36-45.
    View PubMed
  36. Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A. Comparison of alternative biochemical failure definitions' based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995. Int J Radiat Oncol Biol Phys 2003 Nov 15; 57(4):929-43.
    View PubMed
  37. Herman MG, Pisansky TM, Kruse JJ, Prisciandaro JI, Davis BJ, King BF. Technical aspects of daily online positioning of the prostate for three-dimensional conformal radiotherapy using an electronic portal imaging device. Int J Radiat Oncol Biol Phys 2003 Nov 15; 57(4):1131-40.
    View PubMed
  38. Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys 2003 Nov 15; 57(4):915-28.
    View PubMed
  39. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, Vaughan WP, Gradishar WJ, Pisansky TM, Fetting J, Paietta E, Lazarus HM. Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 2003 Jul 3; 349(1):17-26.
    View PubMed
  40. Davis BJ, Pisansky TM, Leibovich BC. Adjuvant external radiation therapy following radical prostatectomy for node-negative prostate cancer. Curr Opin Urol 2003 Mar; 13(2):117-22.
    View PubMed
  41. Schwartz DJ, Davis BJ, Vetter RJ, Pisansky TM, Herman MG, Wilson TM, LaJoie WN, Oberg AL. Radiation exposure to operating room personnel during transperineal interstitial permanent prostate brachytherapy. Brachytherapy 2003; 2(2):98-102.
    View PubMed
  42. Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol 2002 Oct 15; 20(20):4141-9.
    View PubMed
  43. Kruse JJ, Herman MG, Hagness CR, Davis BJ, Garces YI, Haddock MG, Olivier KR, Stafford SL, Pisansky TM. Electronic and film portal images: A comparison of landmark visibility and review accuracy. Int J Radiat Oncol Biol Phys 2002 Oct 1; 54(2):584-91.
    View PubMed
  44. Pisansky TM, Blute ML, Hillman DW, Davis BJ, Haddock MG, Suman VJ, Wilson TM, Zincke H. The relevance of prostatectomy findings for brachytherapy selection in patients with localized prostate carcinoma. Cancer 2002 Aug 1; 95(3):513-9.
    View PubMed
  45. Minsky BD, Pajak TF, Ginsberg RJ, Pisansky TM, Martenson J, Komaki R, Okawara G, Rosenthal SA, Kelsen DP. INT 0123 (radiation therapy oncology group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J Clin Oncol 2002 Mar 1; 20(5):1167-74.
    View PubMed
  46. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE. Outcome of patients receiving radiation for cancer of the esophagus. Results of the 1992-1994 Patterns of Care Study. Classic Papers and Current Comments 2002; 6:742-50.
  47. Schild SE, Pisansky TM. The role of radiotherapy after radical prostatectomy. Urol Clin North Am 2001 Aug; 28(3):629-637.
    View PubMed
  48. Buskirk SJ, Pisansky TM, Atkinson EJ, Schild SE, O'Brien PC, Wolfe JT, Zincke H. Lymph node-positive prostate cancer: evaluation of the results of the combination of androgen deprivation therapy and radiation therapy. Mayo Clin Proc 2001 Jul; 76(7):702-6.
    View PubMed
  49. Sandler H, Shipley WU, Gomella L, Pisansky TM, et al. Genitourinary Cancer Committee. Int J Radiat Oncol Biol Phys 2001; 51(Suppl 2):28-8.
    View PubMed
  50. McCormick B, Strom E, Craighead PS, Kuske R, Hudis C, Ley J, Margolis L, Meyerwitz B, Morris E, Petrek J, Pierce L, Pisansky T, Rabinovitch R, Sneige N, Vicini F, Unger D, Winter K. Radiation Therapy Oncology Group. Research Plan 2002-2006 Breast Cancer Working Group. Int J Radiat Oncol Biol Phys 2001; 51(3 Suppl 2):56-7.
    View PubMed
  51. Leibovich BC, Blute ML, Bostwick DG, Wilson TM, Pisansky TM, Davis BJ, Ramnani DM, Cheng L, Sebo TJ, Zincke H. Proximity of prostate cancer to the urethra: implications for minimally invasive ablative therapies. Urology 2000 Nov 1; 56(5):726-9.
    View PubMed
  52. Davis BJ, Pfeifer EA, Wilson TM, King BF, Eshleman JS, Pisansky TM. Prostate brachytherapy seed migration to the right ventricle found at autopsy following acute cardiac dysrhythmia. J Urol 2000 Nov; 164(5):1661.
    View PubMed
  53. Davis BJ, Haddock MG, Wilson TM, Rothenberg HJ, Bostwick DG, Herman MG, Pisansky TM. Treatment of extraprostatic cancer in clinically organ-confined prostate cancer by permanent interstitial brachytherapy: is extraprostatic seed placement necessary? Tech Urol 2000 Jun; 6(2):70-7.
    View PubMed
  54. Pisansky TM, Davis BJ. Predictive factors in localized prostate cancer: implications for radiotherapy and clinical trial design. Semin Urol Oncol 2000 May; 18(2):93-107.
    View PubMed
  55. Cheng L, Lloyd RV, Weaver AL, Pisansky TM, Cheville JC, Ramnani DM, Leibovich BC, Blute ML, Zincke H, Bostwick DG. The cell cycle inhibitors p21(WAF1) and p27(KIP1) are associated with survival in patients treated by salvage prostatectomy after radiation therapy. Clin Cancer Res 2000 May; 6(5):1896-1899.
    View PubMed
  56. Leibovich BC, Engen DE, Patterson DE, Pisansky TM, Alexander EE, Blute ML, Bergstralh EJ, Zincke H. Benefit of adjuvant radiation therapy for localized prostate cancer with a positive surgical margin. J Urol 2000 Apr; 163(4):1178-82.
    View PubMed
  57. Pisansky TM, Kozelsky TF, Myers RP, Hillman DW, Blute ML, Buskirk SJ, Cheville JC, Ferrigni RG, Schild SE. Radiotherapy for isolated serum prostate specific antigen elevation after prostatectomy for prostate cancer. J Urol 2000 Mar; 163(3):845-50.
    View PubMed
  58. Cheng L, Pisansky TM, Ramnani DM, Leibovich BC, Cheville JC, Slezak J, Bergstralh EJ, Zincke H, Bostwick DG. Extranodal extension in lymph node-positive prostate cancer. Mod Pathol 2000 Feb; 13(2):113-8.
    View PubMed
  59. Coia LR, Minsky BD, Berkey BA, John MJ, Haller D, Landry J, Pisansky TM, Willett CG, Hoffman JP, Owen JB, Hanks GE. Outcome of patients receiving radiation for cancer of the esophagus: results of the 1992-1994 Patterns of Care Study. J Clin Oncol 2000 Feb; 18(3):455-62.
    View PubMed
  60. Cheng L, Pisansky TM, Sebo TJ, Leibovich BC, Ramnani DM, Weaver AL, Scherer BG, Blute ML, Zincke H, Bostwick DG. Cell proliferation in prostate cancer patients with lymph node metastasis: a marker for progression. Clin Cancer Res 1999 Oct; 5(10):2820-3.
    View PubMed
  61. Quella SK, Loprinzi CL, Sloan J, Novotny P, Perez EA, Burch PA, Antolak SJ Jr, Pisansky TM. Pilot evaluation of venlafaxine for the treatment of hot flashes in men undergoing androgen ablation therapy for prostate cancer. J Urol 1999 Jul; 162(1):98-102.
    View PubMed
  62. Cheng L, Cheville JC, Pisansky TM, Sebo TJ, Slezak J, Bergstralh EJ, Neumann RM, Singh R, Pacelli A, Zincke H, Bostwick DG. Prevalence and distribution of prostatic intraepithelial neoplasia in salvage radical prostatectomy specimens after radiation therapy. Am J Surg Pathol 1999 Jul; 23(7):803-8.
    View PubMed
  63. Coia LR, Minsky BD, John MJ, Haller DG, Landry J, Pisansky TM, Willett CG, Hoffman JP, Berkey BA, Owen JB, Hanks GE. The evaluation and treatment of patients receiving radiation therapy for carcinoma of the esophagus: results of the 1992-1994 Patterns of Care Study. Cancer 1999 Jun 15; 85(12):2499-505.
    View PubMed
  64. Davis BJ, Pisansky TM, Wilson TM, Rothenberg HJ, Pacelli A, Hillman DW, Sargent DJ, Bostwick DG. The radial distance of extraprostatic extension of prostate carcinoma: implications for prostate brachytherapy. Cancer 1999 Jun 15; 85(12):2630-7.
    View PubMed
  65. Cheng L, Sebo TJ, Cheville JC, Pisansky TM, Slezak J, Bergstralh EJ, Pacelli A, Neumann RM, Zincke H, Bostwick DG. p53 protein overexpression is associated with increased cell proliferation in patients with locally recurrent prostate carcinoma after radiation therapy. Cancer 1999 Mar 15; 85(6):1293-9.
    View PubMed
  66. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg RJ, Pajak T, Salter M, Benson AB 3rd. Final report of Intergroup Trial 0122 (ECOG PE-289, RTOG 90-12): Phase II trial of neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus. Int J Radiat Oncol Biol Phys 1999 Feb 1; 43(3):517-23.
    View PubMed
  67. Cheng L, Sebo TJ, Slezak J, Pisansky TM, Bergstralh EJ, Neumann RM, Iczkowski KA, Zincke H, Bostwick DG. Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy. Cancer 1998 Nov 15; 83(10):2164-71.
    View PubMed
  68. Loprinzi CL, Pisansky TM, Fonseca R, Sloan JA, Zahasky KM, Quella SK, Novotny PJ, Rummans TA, Dumesic DA, Perez EA. Pilot evaluation of venlafaxine hydrochloride for the therapy of hot flashes in cancer survivors. J Clin Oncol 1998 Jul; 16(7):2377-81.
    View PubMed
  69. Minsky BD, Coia L, Haller DG, Hoffman J, John M, Landry J, Pisansky TM, Willett C, Mahon I, Owen J, Berkey B, Katz A, Hanks G. Radiation therapy for rectosigmoid and rectal cancer: results of the 1992-1994 Patterns of Care process survey. J Clin Oncol 1998 Jul; 16(7):2542-7.
    View PubMed
  70. Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky T. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer 1998 May 1; 82(9):1784-8.
    View PubMed
  71. Minsky BD, Coia L, Haller D, Hoffman J, John M, Landry J, Pisansky TM, Willett C, Mahon I, Owen J, Hanks G. Treatment systems guidelines for primary rectal cancer from the 1996 Patterns of Care Study. Int J Radiat Oncol Biol Phys 1998 Apr 1; 41(1):21-7.
    View PubMed
  72. Hoffman JP, Lipsitz S, Pisansky T, Weese JL, Solin L, Benson AB 3rd. Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study. J Clin Oncol 1998 Jan; 16(1):317-23.
    View PubMed
  73. Coia LR, Minsky BD, John MJ, Haller D, Landry J, Pisansky TM, Willet CG, Mahon I, Owen J, Hanks GE. Patterns of care study decision tree and management guidelines for esophageal cancer. American College of Radiology. Radiat Med 1998; 16:321-7.
    View PubMed
  74. Coia LR, Minsky BD, John MJ, Haller D, Landry J, Pisansky TM, Willet CG, Mahon I, Hanks GE. Patterns of care study decision tree, management guidelines for esophageal cancer. American College of Radiology. Radiat Med 1998; 16(4):321-7.
    View PubMed
  75. Srigley JR, Hutter RVP, Gelb AB, Henson DE, Kenney G, King BF, Raziuddin S, Pisansky TM. Current prognostic factors - renal cell carcinoma - workgroup no. 4. Cancer 1997 Sep 1; 80(5):994-996.
    View PubMed
  76. Pisansky TM, Kahn MJ, Bostwick DG. An enhanced prognostic system for clinically localized carcinoma of the prostate. Cancer 1997 Jun 1; 79(11):2154-61.
    View PubMed
  77. Schomberg PJ, Shanahan TG, Ingle JN, Donohue JH, Kuske RR, Sternfeld WC, Wold L, Cha SS, Petersen IA, Brindle JS, Halyard MY, Bollinger JW, Hawkins R, Pisansky TM. Accelerated hyperfractionation radiation therapy after lumpectomy and axillary lymph node dissection in patients with stage I or II breast cancer: pilot study. Radiology 1997 Feb; 202(2):565-9.
    View PubMed
  78. Pisansky TM, Kahn MJ, Rasp GM, Cha SS, Haddock MG, Bostwick DG. A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer 1997 Jan 15; 79(2):337-44.
    View PubMed
  79. vander Kooy MJ, Pisansky TM, Cha SS, Blute ML. Irradiation for locally recurrent carcinoma of the prostate following radical prostatectomy. Urology 1997 Jan; 49(1):65-70.
    View PubMed
  80. Pisansky TM, Loprinzi CL, Cha SS, Fitzgibbons RJ, Grant CS, Hass AC, et al. Chemioterapia preoperatoria alternata nel trattamento del carcinoma mammario localmente avanzato: Risultati di uno studio pilota. Breast Cancer Digest 1997:12-15.
  81. Coia LR, Minsky BD, John M, Pisansky TM, et al. 1996 decision trees and management guidelines. Semin Radiat Oncol 1997; 7:163-81.
    View PubMed
  82. Schild SE, Pisansky TM, Kozelsky TF, Cha SS, Suman VJ, Burak SL, Ferrigni RG, Myers RP. Radiation therapy for elevated PSA levels after prostatectomy for prostate cancer. ASTRO School of Radiation Oncology: Prostate Cancer Symposium on Long Term Responses to Radiation, Atlanta, GA 1997.
  83. Pisansky TM, Blute ML, Suman VJ, Bostwick DG, Earle JD, Zincke H. Correlation of pretherapy prostate cancer characteristics with seminal vesicle invasion in radical prostatectomy specimens. Int J Radiat Oncol Biol Phys 1996 Oct 1; 36(3):585-91.
    View PubMed
  84. Halyard MY, Grado GL, Schomberg PJ, Weaver AL, Grant CS, Pisansky TM. Conservative therapy of breast cancer. The Mayo Clinic experience. Am J Clin Oncol 1996 Oct; 19(5):445-50.
    View PubMed
  85. Algaba F, Epstein JI, Aldape HC, Farrow GM, Lopezbeltran A, Maksem J, Orozco RE, Pacelli A, Pisansky TM, Trias I. Workgroup 5 - assessment of prostate carcinoma in core needle biopsy - definition of minimal criteria for the diagnosis of cancer in biopsy material. Cancer 1996 Jul 15; 78(2):376-381.
    View PubMed
  86. Pisansky TM, Loprinzi CL, Cha SS, Fitzgibbons RJ Jr, Grant CS, Hass AC, Reuter NF, Wold LE, Ingle JN, Kardinal CG. A pilot evaluation of alternating preoperative chemotherapy in the management of patients with locoregionally advanced breast carcinoma. Cancer 1996 Jun 15; 77(12):2520-8.
    View PubMed
  87. Loprinzi CL, Okuno S, Pisansky TM, Sterioff S, Gaffey TA, Morton RF. Postsurgical changes of the breast that mimic inflammatory breast carcinoma. Mayo Clin Proc 1996 Jun; 71(6):552-5.
    View PubMed
  88. Pisansky TM, Zincke H, Suman VJ, Bostwick DG, Earle JD, Oesterling JE. Correlation of pre-therapy prostate cancer characteristics with histologic findings from pelvic lymphadenectomy specimens. Int J Radiat Oncol Biol Phys 1996 Jan 1; 34(1):33-39.
    View PubMed
  89. Minsky BD, Neuberg D, Kelsen DP, Pisansky TM, Ginsberg R, Benson A 3rd. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus: a preliminary analysis of the phase II intergroup trial 0122. J Clin Oncol 1996 Jan; 14(1):149-55.
    View PubMed
  90. Wold LE, Ingle JN, Pisansky TM, Johnson RE, Donohue JH. Prognostic factors for patients with carcinoma of the breast. Mayo Clin Proc 1995 Jul; 70(7):678-9.
    View PubMed
  91. Minsky B, Neuberg D, Kelsen D, Pisansky TM, Ginsberg R, Benson III A. Neoadjuvant chemotherapy plus concurrent chemotherapy and high-dose radiation for squamous cell carcinoma of the esophagus - a preliminary analysis of the phase II Intergroup trial 0122. Proc Am Soc Ther Radiol Oncol 1995.
  92. Pisansky TM, Halyard MY, Weaver AL, Donohue JH, Grado GL, Grant CS, Hartmann LC, Ingle JN, Schomberg PJ, Wold LE. Breast conservation therapy for invasive breast cancer: a review of prior trials and the Mayo Clinic experience. Mayo Clin Proc 1994 Jun; 69(6):515-24.
    View PubMed
  93. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, Oesterling JE. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993 Nov; 11(11):2158-66.
    View PubMed
  94. Foo ML, McCullough EC, Foote RL, Pisansky TM, Shaw EG. Doses to radiation sensitive organs and structures located outside the radiotherapeutic target volume for four treatment situations. Int J Radiat Oncol Biol Phys 1993 Sep 30; 27(2):403-17.
    View PubMed
  95. Pisansky TM, Ingle JN, Schaid DJ, Hass AC, Krook JE, Donohue JH, Witzig TE, Wold LE. Patterns of tumor relapse following mastectomy and adjuvant systemic therapy in patients with axillary lymph node-positive breast cancer. Cancer 1993 Aug 15; 72:1247-1260.
    View PubMed
  96. Pisansky TM, Schaid DJ, Loprinzi CL, Donohue JH, Schray MF, Schomberg PJ. Inflammatory breast cancer: integration of irradiation, surgery, and chemotherapy. Am J Clin Oncol 1992 Oct; 15(5):376-87.
    View PubMed


Appointments Contact Us Make A Gift Search

Legal restrictions and terms of use applicable to this site

Use of this site signifies your agreement to the terms of use
Copyright © 2009 Mayo Foundation for Medical Education and Research.